The Challenge of Designing Clinical Trials for AIDS-Related Kaposi's Sarcoma

ONCOLOGY

Volumn 12, Issue 6, 1998, Pages 871-883

  Little, Richard F ^a   Pluda, James M ^b   Feigal, Ellen ^c   Yarchoan, Robert ^d  

^a Medicine Branch   (United States)

^b Division of Cancer Treatment   (United States)

^c Division of Cancer Treatment

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCIN SULFATE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; LIPOSOME; PACLITAXEL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CRYOTHERAPY; DRUG RESPONSE; EXCISION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LASER SURGERY; PATHOGENESIS; PATIENT SELECTION; PROGNOSIS; REVIEW;

EID: 0031862219     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Hymes KB, Cheung T, Greene FB, et al: Kaposi's sarcoma in homosexual men - A report of eight cases. Lancet 2:598-600, 1981
2. Urmacher C, Myskowski P, Ochoa M, Jr, et al: Outbreak of Kaposi's sarcoma with cytomegalovirus infection in young homosexual men. Am J Med 72:569-575, 1982.
3. Biggar RJ, Rosenberg PS, Cote T: Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS: Multistate AIDS/Cancer Match Study Group Int J Cancer 68:754-758, 1996.
4. Hermans P, Lundgren J, Sommereijns B, et al: Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years: AIDS in Europe Study Group AIDS 10:911-917, 1996.
5. Kaposi M Idiopathisches multiples Pigmensarkom der Haut. Arch Derm Syph 4:265-273, 1872.
6. Athale UH, Patil PS, Chintu C, et al: Influence of HIV epidemic on the incidence of Kaposi's sarcoma in Zambian children. J Acquir Immune Defic Syndr Hum Retrovirol 8:96-100, 1995.
7. Akhtar M, Bunuan H, Ali MA, et al: Kaposi's sarcoma in renal transplant recipients: Ultrastructural and immunoperoxidase study of four cases. Cancer 53:258-266, 1984.
8. Zisbrod Z, Haimov M, Schanzer H, et al: Kaposi's sarcoma after kidney transplantation: Report of complete remission of cutaneous and visceral involvement. Transplantation 30:383-384, 1980.
9. Nakamura S, Salahuddin SZ, Biberfeld P, et al: Kaposi's sarcoma cells: Long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science 242:426-430, 1988
10. Ensoli B, Nakamura S, Salahuddin SZ, et al: AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243-223-226, 1989.
11. Browning PJ, Sechler JM, Kaplan M, et al: Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 84:2711-2720, 1994.
12. Beral V, Bull D, Darby S, et al: Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339:632-635, 1992.
13. Chang Y, Cesarman E, Pessin M, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994.
14. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332:1181-1185, 1995.
15. Huang YQ, Li JJ, Kaplan MH, et al: Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 345:759-761, 1995.
16. Whitby D, Howard MR, Tenant-Flowers M, et al: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancer 346:799-802, 1995.
17. Humphrey RW, O'Brien TR, Newcomb FM, et al: Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells (PBMCs): Association with KS and persistence in patients receiving antiherpes drugs Blood 88.297-301, 1996.
18. Boshoff C, Schulz TF, Kennedy MM, et al: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1:1274-1278, 1995.
19. Gao SJ, Kingsley L, Li M, et al: KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 2:925-928, 1996.
20. Staskus KA, Zhong W, Gebhard K, et al: Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71:715-719, 1997.
21. Davis DA, Humphrey RW, Newcomb FM, et al: Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide J Infect Dis 175:1071 -1079, 1997.
22. Moore PS, Boshoff C, Weiss RA, et al: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-1744, 1996.
23. Boshoff C, Endo Y, Collins PD, et al: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278:290-294, 1997.
24. Salahuddin SZ, Nakamura S, Biberfeld P, et al: Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 242:430-433, 1988.
25. Karp JE, Pluda JM, Yarchoan R: AIDS-related Kaposi's sarcoma: A template for the translation of molecular pathogenesis into targeted therapeutic approaches. Hematol Oncol Clin North Am 10:1031-1049, 1996.
26. Lundardi-Iskandar Y, Bryant JL, Zeman RA, et al: Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone Nature 375:64-68, 1995.
27. Rabkin CS, Janz S, Lash A, et al: Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 336:988-993, 1997.
28. Northfelt DW: Treatment of Kaposi's sarcoma: Current guidelines and future perspectives. Drugs 48:569-582, 1994.
29. Pluda JM, Broder S, Yarchoan R: Therapy of AIDS and AIDS-associated neoplasms. Cancer Chemother Biol Response Modif 13: 404-439, 1992.
30. Tappero JW, Berger TG, Kaplan LD, et al: Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): A phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol 4:839-846, 1991.
31. Chak LY, Gill PS, Levine AM, et al: Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Clin Oncol 6:863-867, 1988.
32. Groopman JE, Gottlieb MS, Goodman J, et al: Recombinant alpha-2 interferon for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100:671-676, 1984.
33. Krown SE, Real FX, Cunningham-Rundles S, et al: Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 308:1071-1076, 1983.
34. Lane HC, Kovacs JA, Feinberg J, et al: Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 2:1218-1222, 1988.
35. Gill PS, Rarick M, McCutchan JA, et al: Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am J Med 90:427-433, 1991.
36. Laubenstein LJ, Krigel RL, Odajnyk CM, et al: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2:1115-1120, 1984.
37. Gill PS, Miles SA, Mitsuyasu RT, et al: Phase I AIDS Clinical Trials Group (075) study of Adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 8:1695-1699, 1994.
38. Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364, 1996.
39. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920, 1995
40. Goebel FD, Goldstein D, Goos M, et al: Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer 73:989-994, 1996.
41. Gill PS, Espina BM, Muggia F, et al: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13:996-1003, 1995.
42. Presant CA, Scolaro M, Kennedy P, et al: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341:1242-1243, 1993.
43. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997.
44. Stewart J, Jablonowksy H, Goebel F, et al: A randomized comparative trial of Doxil vs bleomycin and vincristine (BV) in the treatment of AIDS-related Kaposi's sarcoma (abstract A190). Proc Am Soc Clin Oncol, 1997.
45. Saville MW, Lietzau J, Pluda JM, et al: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel Lancet 346:26-28, 1995.
46. Gill P, Scadden D, Groopman J, et al: Low-dose paclitaxel (Taxol) is highly effective in the treatment of patients with advanced AIDS-related Kaposi's sarcoma (abstract A35). Presented at the 1st National AIDS Malignancy Conference, April 1, 1997, Bethesda, Maryland.
47. Dezube BJ: Clinical presentation and natural history of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am 10:1023-1029, 1996.
48. Antinori A, Izzi I, Ammassari A, et al: Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. J Cancer Res Clin Oncol 118:635-636, 1992.
49. Volberding PA, Abrams DI, Conant M, et al: Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103:335-338, 1985.
50. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 7:1201-1207, 1989.
51. Garay SM, Belenko M, Fazzim E, et al: Pulmonary manifestations of Kaposi's sarcoma. Chest 91:39-43, 1987.
52. Friedman SL, Wright TL, Altman DF: Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology 89:102-108, 1985.
53. Bower M, Howard M, Gracie F, et al: A Phase II study of thalidomide for Kaposi's sarcoma: activity and correlation with KSHV DNA load (abstract A35). Presented at the 1st National AIDS Malignancy Conference, April 1, 1997, Bethesda, Maryland.
54. Welles L, Little R, Wyvill k, et al: Preliminary results of a phase II study of oral thalidomide in patients with HIV infections and Kaposi's sarcoma (KS) (abstract A21). Presented at the 1st National AIDS Malignancy Conference, April 1, 1997, Bethesda, Maryland.
55. Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and theiapeutic strategies. Semin Oncol 24:203-218, 1997.
56. Feigal E, Roen JV, Justice R, et al: Kaposi's sarcoma response criteria: Issues identified by the National Cancer Institute, Food and Drug Administration, and the AIDS Malignancy Consortium (abstract A22). Presented at the 1st National AIDS Malignancy Conference, April 1, 1997, Bethesda, MD.
57. Ohori M, Wheeler TM, Scardino PT: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer: Clinicopathologic correlations. Cancer 74:104-114, 1994.
58. Orfanos CE, Husak R, Wolfer U, et al: Kaposi's sarcoma: A reevaluation. Recent Results Cancer Res 139:275-296, 1995.
59. Mitsuyasu RT, Taylor JMG, Glaspy J, et al: Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy. Cancer 57:1657-1661, 1986.
60. Tambussi G, Repetto L, Torri V, et at: Epidemic HIV-related Kaposi's sarcoma: a retrospective analysis and validation of TIS staging. GICAT: Gruppo Italiano Collaborativo AIDS e Tumori Ann Oncol 6:383-387, 1995.
61. Krown SE, Testa MA, Huang J: AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 15:3085-3092, 1997
62. Taylor J, Afrasiabi R, Fahey JL, et al: Prognostically significant classification of immune changes in AIDS with Kaposi's sarcoma Blood 67:666-671, 1986.
63. Cadranel JL, Kammoun S, Chevret S, et al. Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. Thorax 49:958-960, 1994.
64. Meduri GU, Stover DE, Lee M, et at Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: Clinical, radiographic, and pathologic manifestations. Am J Med 81:11-18, 1986.
65. Ensoli B, Barillari G, Salahuddin SZ, et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345:84-86, 1990.
66. Henry K, Worley J, Sullivan C, et al: Documented improvement in late stage manifestations of AIDS after starting ritonavir in combination with two reverse transcriptase inhibitors (abstract A356). Presented at the 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, Washington, DC.
67. Murphy M, Armstrong D, Sepkowitz KA, et al: Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 11:261-262, 1997.
68. Nakamura S, Sakurada S, Gill P, et al Glucocorticoid enhanced in vitro growth of AIDS KS associated Kaposi's sarcoma-derived spindle cells. AIDS Res Hum Retroviruses 7:216-217, 1991.
69. Gill PS, Loureiro C, Bernstein-Singer M, et al: Clinical effect of glucocorticoids on Kaposi's sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 110:937-940, 1989.
70. Gill PS, Lunardi-Ishkandar Y, Louie S, et al: The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 335:1261-1269, 1996
71. Yarchoan R, Broder S: Preliminary results on the use of dideoxynucleosides in the therapy of AIDS, in Chanock RM, Lerner RA, Brown F, et al (eds): Vaccines 87: Modern Approaches to New Vaccines: Prevention of AIDS and other Viral, Bacterial, and Parasitic Diseases, pp 214-224 Cold Spring Harbor. New York, Cold Spring Harbor Laboratory Press, 1987.
72. Conant MA, Opp KM, Poretz D, et al: Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir AIDS 11:1300-1301, 1997.
73. Hammer SM, Squires KE, Hughes MD, et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337:725-733, 1997.
74. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine. and Iamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739, 1997.
75. Marco M, Majchrowicz M: The KS Project Report: Current Issues in Research & Treatment of Kaposi's Sarcoma. New York, Treatment Action Group, 1996